Ikarian Capital’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Ikarian Capital’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-130,845	Closed	-$497K	–	220
2020 Q1	$497K	Hold	130,845	–	–	0.04%	134
2019 Q4	$666K	Buy	+130,845	New	+$692K	0.11%	87

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Ikarian Capital's PGNX Position: Q2 2020 in Review

Ikarian Capital sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 130,845 shares — an estimated $497K sold.

Ikarian Capital first reported a position in PGNX in Q4 2019 and held it in 2 quarters. The position peaked at $666K in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Ikarian Capital reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Ikarian Capital sold 130,845 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $497K.
Ikarian Capital first reported a position in Progenics Pharmaceuticals Inc in Q4 2019 and held it in 2 quarters.
Ikarian Capital's Progenics Pharmaceuticals Inc position peaked at $666K in Q4 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.